An Inflammation Marker Correlates Well With Mortality Rates

Here is one of many clear signs to show that chronic inflammation is something to be avoided: “Inflammation, oxidative damage, and platelet activation are hypothesized biological mechanisms driving the disablement process. The aim of the present study is to assess whether biomarkers representing these mechanisms predicted major adverse health-related events in older persons. … Data are from 2,234 community-dwelling nondisabled older persons enrolled in the Health Aging and Body Composition study. Biomarkers of lipid peroxidation, platelet activation, and inflammation (serum concentrations of interleukin-6) were considered as independent variables of interest and tested in Cox proportional hazard models as predictors of (severe) mobility disability and overall mortality. … The sample’s (women 48.0%, whites 64.3%) mean age was 74.6 (SD 2.9) years. During the follow-up (median 11.4 years), 792 (35.5%), 269 (12.0%), and 942 (42.2%) events of mobility disability, severe mobility disability, and mortality occurred, respectively. … Only interleukin-6 showed significant independent associations with the onset of all the study outcomes. … The inflammatory marker interleukin-6 is confirmed to be a robust predictor for the onset of negative health-related events.”

Link: http://www.ncbi.nlm.nih.gov/pubmed/22389462

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Source:
http://www.longevitymedicine.tv/feed/

A Cancer Suppression Mutation that Also Extends Life

Most known cancer suppression genes and mutations shorten life in laboratory mice, as they suppress the mechanisms of cell replication needed to maintain tissues. There are exceptions that have emerged as researchers find more sophisticated methods of genetic engineering to work around these limitations, but this life-extending example of gene engineering seems to be more straightforward than most: “Mice with an extra dose of a known anti-cancer gene lose weight even as their appetites grow. Not only that, but [the] animals also live longer, and that isn’t just because they aren’t getting cancer, either. … One of the animals’ youthful secrets is hyperactive brown fat, which burns energy instead of storing it. The findings add to evidence that tumor suppressors aren’t designed only to protect us against cancer, the researchers say. They also point to new treatment strategies aimed to boost brown fat and fight aging. … Tumor suppressors are actually genes that have been used by evolution to protect us from all kinds of abnormalities. … In this case, the researchers studied a tumor suppressor commonly lost in human cancers. Mice with an extra copy of the gene known as Pten didn’t get cancer, but that’s not the half of it. Those mice were also leaner, even as they ate more than controls … That suggested that the animals were experiencing some sort of metabolic imbalance – and a beneficial one at that. Cancer protection aside, the animals lived longer than usual. They were also less prone to insulin resistance and had less fat in their livers. Those benefits seem to trace back to the fact that those Pten mice were burning more calories thanks to overactive brown fat.”

Link: http://www.sciencedaily.com/releases/2012/03/120306131252.htm

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Source:
http://www.longevitymedicine.tv/feed/

Eating healthy key for latest centenarian

by BY DANIELLE STANTON stanton@monroenews.com , last modified March 16. 2012 12:07PM

Evening News photo by BRYAN BOSCH Josephine Hetu is turning 100 today.

Spread The News

Josephine Hetu is celebrating her 100-year birthday today.

The secret to her longevity: tomatoes.

Her niece, Patty Hochradel, said Ms. Hetu would often demand tomatoes. She also eats blueberries and walnuts. Not only would she eat healthy and exercise, she would educate herself on fitness.

I read all the health articles I came across, Ms. Hetu said in a recent interview. I like tomatoes and I like salads. I tried to eat right. Thats whats kept me healthy.

Her secret to keeping her skin young and healthy looking: Wash with hot water, rinse with cold and no soap.

The Elderly Solutions resident is not surprised she has lived so long because she kept such good care of herself. Not only would she eat right, but she would do leg and stomach exercises in bed every morning.

Shes very proud of the fact that she has all her own teeth and has no cavities.

Continue reading here:
Eating healthy key for latest centenarian

Popping pills at 10 years old

17 March 2012 Last updated at 22:20 ET By Philippa Roxby Health reporter, BBC News

Life expectancy has changed dramatically in a century.

In 1908, half the UK population was dead by 60 and in 1948, when the contributory state pension was introduced, half the population was dead by the age of 72.

Falling mortality rates, as a result of advances in science and medicine, mean the average UK man and woman can expect to live into their 80s, perhaps even to the age of 100, but what will the quality of our lives be like?

And will we have to resort to more and more drugs to keep us alive?

The longer we live, the more prone we are to chronic diseases such as heart disease, diabetes, stroke and cancer.

Drugs can help control and reduce the symptoms of these conditions and increase our longevity, but the danger is that we will come to rely on them too much.

The population appear to be saying that 'I can eat as much as I like and take a pill to stop the effects.' It is very worrying

Professor Sarah Harper, director of the Oxford Institute of Population Ageing at Oxford University, believes that keeping more people alive for longer and longer will come at a cost.

"We have to ask if we wish our future to be one where individuals, at increasingly younger ages, pop pills rather than eat healthily, stop smoking, reduce alcohol and take up exercise.

Visit link:
Popping pills at 10 years old

Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline?

Tweet 


Adam
Feuerstein
(phama and biotech writer with TheStreet.com) has designed his own rule. 

For those who know or follow Adam, this will come as no surprise.  He is
neither short of rules nor opinion and is never shy in his vivid expression of
either.  But this rule is more than a simple expression of informed
opinion. It was born of hard data analysis and has yet to be broken.  In
Adam’s own words, this is how he and his colleague (Mark J. Ratain) came to the
rule they coined the Feuerstein-Ratain Rule:
[We] analyzed the outcomes of
59 phase III clinical trials of cancer drugs going back 10 years, stratified by
the market value of the companies four months prior to trial results being
announced. What we found was a remarkable difference between the market values of companies that had positive and negative
announcements
.  (the list of companies/products used can be found here
)
Specifically, the median market capitalization was approximately
80-fold greater for the companies with positive trials vs. companies with
negative trials. There were no positive trials among the 21 micro-cap companies
(companies with less than $300 million market capitalization) whereas 21 of 27
studies reported by the larger companies analyzed (greater than $1 billion
capitalization) were positive.
The
editorial, entitled “Oncology Micro-Cap Stocks: Caveat Emptor!”, can be
found in Journal of the National Cancer
Institute
 
(JNCI) at http://jnci.oxfordjournals.org/content/early/2011/09/26/jnci.djr375.full.
They identified
drugs that were undergoing evaluation in phase III trials or for regulatory approval
by the US FDA between January 2000 and January 2009. 
They calculated the
company value based on the market value of primary drug sponsor roughly
three months prior to the release of the data.  They concluded that
whether or not a company had pharma in place was not determinative of a drug’s
success but rather that partnerships or acquisitions by Big Pharma can play a
role in determining a drug’s success only in that these deals may increase the
market value of the primary drug sponsor.  That value was the
determinative factor.
This
is Adam’s summary of the analysis they did that led to the “Feuerstein-Ratain Rule”.  
Below
are the important snippets from the analysis behind the rule:
The “Feuerstein-Ratain
rule” is derived from an analysis of 59 phase III clinical trials of
cancer drugs conducted over the past 10 years. We actually had no say
whatsoever in the selection of cancer drugs used in the analysis. The list was
put together by health economist Allan Detsky of Toronto’s Mount Sinai Hospital
and his co-authors as part of their paper published in the Journal of the National Cancer
Institute
 suggesting that
doctors entrusted with conducting late-stage cancer drug clinical trials are
using advanced knowledge of the results of these pivotal studies to engage in
illegal insider trading.
Ratain and I used the same list of 59 cancer drug clinical trials,
re-analyzed by market value of the drug sponsors, to debunk Detsky’s
insider-trading theory. That’s how the “Feuerstein-Ratain rule” came
about, and we published our conclusions in the JNCI alongside Detsky’s paper.
To restate our findings:  No positive trials among the
21 micro-cap companies
(companies with less than $300 million market
capitalization) whereas 21 of 27 studies reported by the larger companies analyzed
(greater than $1 billion capitalization) were positive
There were 21 companies on the
list with market values of $300 million or less, with a 0% success rate in
phase III cancer drug clinical trials.
The list also contained 11 companies with market caps between
$300 million and $1 billion. The clinical trial success rate for this mid-tier
or second strata group was 18%. (Two positive clinical trials out of 11.)
Lastly, there were 21 of 27 studies reported by the larger
companies analyzed (greater than $1 billion capitalization) that were positive,
or a 78% success rate.
So
what interesting for us in cell therapy?
It
is interesting to note that the Feuerstein-Ratain Rule is
limited to oncology drugs and all the companies behind them were public. 
Adam has not – nor has anyone else to the best of my knowledge – looked at how
the rule may or may not translate outside of oncology.

Of
the cell therapy companies to have received market approval in US or EU in the
past 10 years, one was public (DNDN) and one was still private (TIG) and went
public shortly therafter in the same year. TiGenix was a private company and is
not in oncology so the analysis arguably does not apply.  However,
Dendreon’s Provenge is an oncology ‘drug’.  Dendreon had a market cap of
about $430M in the 4 months before its ph III data was announced and as such
would have fallen in the 18% likelihood of success category.  That sounds
about right.

I thought it might be interesting to do our own look at what the Rule might say about the pipeline of late-stage cell-based oncology trials.  Following
is a list of cell therapy companies currently in ph III or II/III for oncology:

* Trial not expected to complete until Q1
2014 so a lot could happen to the market cap in 2012/13.  It also could be
argued that this is not an oncology treatment as per original data set but a
treatment of the side  effects of the primary cancer treatment.
** Trial not expected to complete until Q1
2014 so a lot could happen to the market cap in 2012/13.
*** It could be argued that this is not an
oncology treatment as per original data set but 
a treatment of the side effects of the primary cancer treatment.
+ It could be argued this is not a cell
therapy though we would argue it is.  Others might argue that as a phase II/III
trial with only 60 patients this may not be powered to be a pivotal oncology trial.
^ Trial currently in “suspension” so this
date may be pushed out or trial terminated. It also could be argued that this
is not an oncology treatment as per original data set but a treatment of
the effects of the primary cancer treatment.  Others might argue that as a phase II/III trial with
only 70 patients this may not be powered to be a pivotal oncology trial.
Conclusion:  At the moment it looks like both NovaRx and ERYtech will go to their phase III data completion (June and October 2012 respectively) as private companies.  To qualify under the rule, Cell Medica would have to go public within the year and/or Kiadis would have to go public within the next 25 months. 

The only
companies with cell-based oncology products currently in late-stage trials to
which the Rule would apply are Molmed’s HSV-TK and Newlink Genetics’ HyperAcute
Pancreas.  

Assuming both MolMed and NewLink’s trials progress as planned, we won’t know what
they look like under the rule until around Sept 2013 at which time we can assess their
market cap against the Rule.  At the moment, it’s looking pretty bleak for
both of them according to the Rule though at least the NLNK price has been
going in the right direction of late.  

Certainly one would expect trading
volume to dramatically increase on both these as their trial completion dates
near.  It remains to be seen how this will impact price but they would
have to  dramatically increase in market cap (double or triple) to succeed
as the Rule predicts. 

Naturally, this is just one way of looking at the world and, of course, this rule – as with all rules – is meant to be broken.
  

Source:
http://feeds.feedburner.com/CellTherapyBlog

Source:
http://www.longevitymedicine.tv/feed/

6 Surprising Behaviors That Age You

When you think of factors that prematurely age you, your mind probably turns to smoking, overeating, or excessive stress. And if you've been following the news, you might add tanning to the list (it makes you more susceptible to skin cancer--and we won't even get started on the wrinkles and sun spots.) But what you might not know is that your exercise patterns, listening habits, and even your cooking style can negatively affect your life. Luckily, you can make changes. Read on for tips on how to counteract these six surprising behaviors that age you:

[See: Popular but Dangerous: 3 Vitamins That Can Hurt You]

Overheating your food. Think twice before constantly grilling and frying your meals. Foods cooked at high temperatures can produce compounds that increase inflammation, which damages the body's cells and is increasingly fingered as a driver of many diseases, such as cancer. The highest levels of these compounds, called advanced glycation end products (AGEs), are in fatty foods and meats (think steak), while the lowest levels are in carbohydrate-rich foods like vegetables, says Melina Jampolis, a physician nutrition specialist and author of The Calendar Diet: A Month by Month Guide to Losing Weight While Living Your Life. "Longer cooking time, higher heat, and less moisture during cooking affect levels formed," she explains. Just like the acronym states, AGEs are thought to speed up the aging process, and they have been linked to heart disease, diabetes, and other age-related diseases, she says. Try cutting back on fast food, processed-packaged foods, and higher-fat meats, and eating fruits and veggies rich in antioxidants, like grapefruit and spinach, to prevent the formation of AGEs, she says. (Drinking tea and a little red wine counts, too.) Also helpful: Cooking foods at lower temperatures for longer periods of time, and increasing moisture during cooking. So steam that shrimp instead of sauting it!

[See: Red Meat Shortens Life? What to Do]

Running uphill or up stairs. All running isn't always good. Uphill running (in particular) places additional stress on the knees and ankles, reports the American Orthopaedic Society for Sports Medicine. "There is at least a four-fold increase placed on our knee joint [with uphill running], and this can lead to premature breakdown of cartilage, also known as arthritis," says Moshe Lewis, chief of physical medicine and rehab at California Pacific Medical Center, St. Luke's Campus. If you're just beginning a running program, the AOSSM cautions against uphill running at first. Even if you're an experienced runner, take care with steep inclines. After all, the ideal running surface is "flat, smooth, resilient, and reasonably soft," says the AOSSM.

Listening to loud music and loud noises. Yes, blasting your favorite songs is fun, but if you keep doing it, you may not get to enjoy those tunes in a few years. That's because loud noises can put you at risk for premature hearing loss, with sounds louder than 85 decibels able to cause permanent loss, reports the American Speech-Language-Hearing Association. A blow dryer is 80 to 90 decibels, the subway is 90 decibels, and the maximum output of some MP3 players is 110 decibels, ASHA reports. In fact, MP3 players pose a serious hazard to hearing to which teens are especially vulnerable, according to recent research from Tel Aviv University. To enjoy music for years to come, listen to your MP3 player at half volume, ASHA advises. And if you don't have protection, like ear plugs, don't expose yourself to loud noises for prolonged periods.

[See: 11 Health Habits That Will Help You Live to 100]

Bad posture when using tech devices. When you gaze down at a tech device, especially when it's in your hand or lap, your posture suffers. "Poor posture mechanics lead to rounded shoulders and neck strain," says Lewis. But you don't have to give up your beloved tablet laptop or smartphone to avoid being permanently hunched over. Just place your device higher up--like on a table--to prevent lower-gaze angles, suggests a recent study by Harvard School of Public Health researchers. Also sit straight up, and take breaks every 10 minutes, says Lewis. "The damage can be reversed," he says, "but there is a limited window."

Not maintaining your balance. As we age, we lose our balance, which can spell falls and fractures. (Each year, more than 1.6 million older Americans land in the emergency room because of fall-related injuries, according to the National Institute on Aging.) "Balance goes unnoticed until it's gone," says Lorraine Maita, a New Jersey-based internist and author of Vibrance for Life: How to Live Younger and Healthier. But you don't have to lose it. To avoid being off-balance before your time, "try sports that require agility, like tennis," she says. Stability balls, yoga, and dance are also good bets.

Not wearing sunglasses. You must protect your eyes from UV radiation. Spending long hours exposed to these rays without adequate protection can raise the risk of cataracts (a clouding of the eye lens that can blur vision), snow blindness (a temporary burn to the cornea), and skin cancer around the eyelids, according to the Environmental Protection Agency. If you're around snow, water, or sand, know that these elements reflect UV rays, which can amplify the amount reaching your eyes and skin. The fix: Wear sunglasses outside, even on cloudy days, advises the EPA. Make sure the label says they block 99 to 100 percent of UVA and UVB rays. And if your new shades make you look good, too? Well, that's just a bonus.

Here is the original post:
6 Surprising Behaviors That Age You

Red Meat a Ticket to Early Grave, Harvard Says

Just in time to spoil the promise of warm-weather picnics, Harvard scientists have found that daily consumption of red meat particularly the kind you might like to grill may significantly increase your risk of premature death.

While this much has long been suspected, perhaps even by you, the Harvard-led study is the first nuanced analysis to calculate the risk that a serving of red meat can have on your longevity compared with other protein sources.

The study measures, for example, how much one could expect to lower their risk of early death by replacing pork and beef with poultry, fish, nuts or beans can lower the risk of early death; they found chicken was at least as healthy an alternative to red meat as beans and whole grains.

"This paper does not give a green light to a low-fat, high-carb diet," senior author Frank Hu of Harvard School of Public Health (HSPH) told LiveScience. "Instead, it underscores the importance of types or quality of protein." [7 Foods Your Heart Will Hate]

The study was published today (March 12) online in the journal Archives of Internal Medicine.

120,000 people can't be wrong

The researchers, led by An Pan at HSPH, tapped into two longitudinal health studies the Health Professionals Follow-Up Study, and the Nurses' Health Study which capture health and dietary information from approximately 120,000 adults who were free of cardiovascular disease and cancer at the onset of the study and followed for up to 28 years.

For these subjects, 20 percent of whom died during the study, one daily serving of unprocessed red meat such as steak or pork chops was associated with a 13 percent increased risk of dying during the study. One daily serving of processed red meat, such as a hot dog or bacon, was associated with a 20 percent increased risk.

Conversely, replacing one serving of red meat with one serving of a healthy protein source was associated with a lower mortality risk: 19 percent lower when the meat was replaced with nuts; 14 percent for poultry; 14 percent for whole grains; 10 percent for legumes; 10 percent for low-fat dairy products; and 7 percent for fish. [Top 10 Leading Causes of Death]

"This study provides clear evidence that regular consumption of red meat, especially processed meat, contributes substantially to premature death," said Hu.

Go here to see the original:
Red Meat a Ticket to Early Grave, Harvard Says

MDPrevent Preventive Medicine & Learning Centers Retains Simply the Best PR to Launch National Program

DELRAY BEACH, Fla., March 12, 2012 /PRNewswire/ --MDPrevent (www.MDPrevent.net) Preventive Medicine & Learning Centers, based in Delray Beach, FL, announced today retention of Simply the Best Public Relations (www.simplythebestpublicrelations.com) as its PR firm to position founder Steven Charlap, MD, MBA as a visionary in preventive medicine.

Dr. Charlap, who received his MBA from Harvard and his MD from New York University, was the founder of the largest medical and dental practice in the United States serving extended care facilities. He witnessed what happened to 5 million people who didn't take adequate care of their health, ended up being institutionalized and who became dependent on the kindness of strangers. This experience fuels his commitment to help future generations avoid the same fate.

The mission of Charlap and the medical professionals at MDPrevent is to increase longevity, improve well-being, and restore the vitality of their patients. Their goal is to help people reduce health care costs, stay healthy, get off unnecessary medications and supplements, primarily through preventive services and education provided at no cost to Medicare beneficiaries. MDPrevent's team approach to preventing chronic illness includes doctors, nurse practitioners, psychologists, nutritionists, fitness experts, and health educators.

According to Dr. Charlap, "Diabetes, heart diseases, cancer, depression, dementia, and obesity, are the world's leading cause of preventable death. By addressing the root causes of these diseases instead of just reducing symptoms, MDPrevent's medical professionals help people enjoy longer, happier lives because the longer you live, the healthier you've been."

"Our targeted publicity campaigns will introduce MDPrevent and Dr. Charlap to consumers and other healthcare professionals as a practical solution to the tsunami of chronic diseases crippling our society," says Kim Morgan, President of Simply the Best PR. She adds, "Dr. Charlap's passion is to change the healthcare status quo. Due to his previous success, he is not motivated by personal financial gain; rather, he is on a mission to educate society how the right lifestyle choices can improve quality of life and longevity."

MDPrevent 5130 Linton Blvd. Suite H1 Delray Beach, FL 33484 (561) 807-2561 http://www.mdprevent.net

Read more here:
MDPrevent Preventive Medicine & Learning Centers Retains Simply the Best PR to Launch National Program

A New Study Addressing the Benefits of Using the SELPHYL® System with Fat Transfer Published in the American Journal …

WAYNE,N.J., March 12, 2012 /PRNewswire/ --Aesthetic Factors, LLC, an emerging company focused on autologous, point-of-care systems in regenerative medicine, is pleased to announce that a study examining the efficacy of the SELPHYL System used with fat grafting procedures has been published in Volume 29 Issue 1 of the American Journal of Cosmetic Surgery.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/a-new-study-addressing-the-benefits-of-using-the-selphyl-system-with-fat-transfer-published-in-the-american-journal-of-cosmetic-surgery-142117143.html

SELPHYL is an ultrapure Platelet-Rich Fibrin Matrix (PRFM) preparation. Using a small amount of the patient's own blood, the system isolates and prepares PRFM for injection back into the patient. SELPHYL naturally produces and releases a host of biologic growth factors that have been shown to promote tissue regeneration.

In the study entitled, "Benefits of Autologous Fat Grafting Using Fat Mixed with Platelet-Rich Fibrin Matrix (PRFM) SELPHYL," Lead Researcher, Richard Goldfarb, MD, FACS Center for SmartlipoLanghorne, PA analyzed the potential of SELPHYL to increase vascularity in fat transfer thus improving longevity potential. Fat grafting is used for facial rejuvenation, primarily to smooth out wrinkles and restore volume to areas of the face that have been deflated over time. However, historically, the long-term survival rates of autologous fat grafting have been variable. Consequently, fat grafting does not always produce the long-term correction for which patients are looking. The duration of fat transfer alone varies considerably, lasting anywhere from 6 months to several years.

The study follows a 37-year-old female who had fat from her outer thighs injected into her lower abdominal area. In one site on her lower abdomen, 8ccs of fat was injected; in another site, 8ccs of fat combined with 4ccs of SELPHYL was injected. After eight weeks, the tissue was analyzed, showing viable fat in both sites, but the area injected with SELPHYL showed an increase in blood vessels, which is key to improving the chances of long-term fat survival. The researchers concluded that the fat mixed with SELPHYL improved fat cell survival.

"After 3 to 16 months of consistent follow-up, outcomes reflect that SELPHYL has given fat grafts not only a higher rate of permanency, but also a greater take rate," commented researcher Aaron L. Shapiro, M.D., a facial plastic surgeon in Bryn Mawr, PA. "SELPHYL has been easy to use and patients have been very pleased with their results. Preliminary findings reflect that the addition of SELPHYL enhances and improves the long-term survival of my fat grafts."

"Any technique or mechanism that demonstrates efficacy in enhancing the graft survival would be very beneficial in cosmetic surgery. We are confident that this important clinical finding will lead to wider acceptance of the SELPHYL plus fat technique," writes Dr. Goldfarb.

SELPHYL is only available through qualified healthcare practitioners. Over 350 physicians and clinics worldwide currently feature the SELPHYL System.

The rest is here:
A New Study Addressing the Benefits of Using the SELPHYL® System with Fat Transfer Published in the American Journal ...

Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of …

CLEARWATER, FL--(Marketwire -03/12/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA).

Biostem CEO, Dwight Brunoehler stated, "The Company is now positioned for growth and international expansion. Adding a world class team of clinical, laboratory, and regulatory experts for our Scientific and Medical Board of Advisors to guide our pursuits is essential. Dr. Prendergast brings a wealth of experience not only in the scientific aspects of stem cell use in regenerative medicine, but also in forging research and international economic development opportunities."

Dr. Prendergast is a busy clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in biophysics and Psychology, as well as his medical degree, at Pennsylvania State University. His general surgery residency was for five years at the University of Massachusetts Medical School. His cardiothoracic surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included pediatric cardiac surgery at Children's Hospital of LA, along with thoracic transplant fellowships at University of Southern California in Los Angeles and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of their staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transplantation and Mechanical Assistance.

Regarding his appointment to the Biostem U.S. Scientific and Medical Board of Advisors, Dr. Prendergast said, "I am looking forward with excitement to working again with Dwight at Biostem. The expansion plan is sound, well paced, and will afford improved quality of life opportunities to many people around the world."

About Biostem U.S., Corporation

Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Kerry D'Amato, Marketing Director at 727-446-5000.

View post:
Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of ...

OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks …

MIAMI & JUPITER, Fla.–(BUSINESS WIRE)–

OPKO Health, Inc. (NYSE: OPK – News) and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinsons disease. Under the terms of the agreement, The Scripps Research Institute has granted to OPKO Health exclusive worldwide rights to develop, manufacture and commercialize SR 3306 and related compounds that inhibit a class of enzymes called jun-N-terminal kinsases (JNK) that play an important role in neuron survival. The new compound, a small molecule known as SR-3306, would potentially be the first to protect the brain from the ravages of Parkinson’s disease.

This licensing agreement will help insure that the development of this promising compound keeps moving forward, said Scripps Research Professor Philip LoGrasso, whose laboratory has led the research on the compound to date. This is one of the best opportunities we have for the development of an effective neuroprotective treatment for Parkinsons patients.

We are excited to be working with Dr. LoGrasso and The Scripps Research Institute to develop this important compound which could prevent the progression of Parkinsons disease and not just treat the symptoms of the disease, said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. Parkinson’s disease, a degenerative neurological disorder that reduces the brain’s ability to produce dopamine, affects about one million Americans. Currently prescribed drugs for Parkinsons disease including levodopa and so-called MAO-B inhibitors can counteract symptoms of the disease but not stop its progression.

SR-3306 was described in a pair of studies led by Dr. LoGrasso and published in February 2011 in the journal ACS Chemical Neuroscience.

About The Scripps Research Institute

The Scripps Research Institute is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, Scripps Research has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including three Nobel laureates work toward their next discoveries. The institute’s graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see http://www.scripps.edu.

About OPKO Health, Inc.

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

Forward Looking Statements:

Read the original:
OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks …

Source:
http://www.longevitymedicine.tv/feed/

QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson’s Disease

BERWYN, PA.–(BUSINESS WIRE)–

QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit.

Mutations and overexpression of alpha-synuclein (a-SYN) have been shown to cause familial PD while genetic association studies indicate a-SYN is a key risk factor in sporadic PD. Evidence suggests that therapies that can reduce a-SYN expression may block its pathogenic actions and therefore be useful in treating PD. In vitro studies conducted at Massachusetts General Hospital demonstrate that Posiphen lowers a-SYN levels by inhibiting a-SYN translation.

To establish efficacy in PD, Posiphen will be tested in transgenic mice engineered by Dr. Nussbaum’s group at UCSF that express mutant human a-SYN. These mice exhibit early gastrointestinal dysfunction at three-months and motor abnormalities later in life, mimicking what is found in PD patients. Studies will be conducted to test, among other things, Posiphen’s ability to reverse these abnormalities to establish pre-clinical efficacy as a basis for future testing in humans.

“Our animal model is based on the initial work we did 15 years ago identifying alpha-synuclein as the first human gene which, when mutated, causes Parkinson disease,” said Dr. Robert Nussbaum. “Our model recapitulates the early signs of the disease and is well suited to test therapies directed toward regulating alpha-synuclein expression either on the gene or on the protein level.”

“Alpha-synuclein is a high-priority target for our Foundation, as there is evidence that it plays an important role in both genetic and idiopathic cases of PD,” said Kuldip Dave, PhD, associate director of research programs at MJFF. “QR Pharma’s drug Posiphen has been shown to block the synthesis of alpha-synuclein. By decreasing alpha-synuclein levels in the brain, Posiphen could potentially be a novel treatment for PD.”

“We are pleased that The Michael J. Fox Foundation for Parkinson’s Research sees the potential of Posiphen in the treatment of Parkinson’s disease,” said Maria Maccecchini, Chief Executive Officer of QR. “We look forward to working with the excellent research teams led by Dr. Nussbaum and Dr. Rogers.”

About Posiphen . QR’s lead Posiphen is a small orally active compound with high blood brain barrier permeability, which lowers levels of toxic protein aggregates. It targets the mRNA of a number of proteins that are overexpressed in several neurological disorders such as Alzheimer’s disease, Parkinson’s disease and Down syndrome. It is in clinical development as an oral treatment for Alzheimer’s disease. Posiphen reduces the rate of synthesis of amyloid precursor protein (APP) in cell cultures, normal, transgenic and trisomic mice as well as in humans. Posiphen also inhibits the synthesis of tau and alpha-synuclein in mice and humans. These neurotoxic aggregating proteins induce dysfunction, neuroinflammation and lead to cognitive impairment and neurodegeneration.

About QR Pharma, Inc. Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer’s disease (AD), Parkinson’s disease (PD) and Down syndrome (DS). QR currently has three product development programs – Posiphen for early stage AD and PD and BNC for advanced AD. For more information on QR Pharma, please visit the company’s website, http://www.qrpharma.com.

About The Michael J. Fox Foundation for Parkinson’s Research. As the world’s largest private funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $285 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Now through December 31, 2012, all new and increased giving to The Michael J. Fox Foundation, as well as gifts from donors who have not given since 2010 or earlier, will be matched on a dollar-for-dollar basis with the $50-million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki.

Link:
QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson's Disease

Source:
http://www.longevitymedicine.tv/feed/

Discover New Treatments For Parkinson’s Disease

Nearly one million people in the United States are living with Parkinson’s Disease. Although there is no cure, there are medications and surgical options that can help manage symptoms optimally.

Winthrop-University Hospital’s Perspectives in Health series will offer a free seminar for the public, “Discover New Treatments for Parkinson’s Disease,” on Tuesday,

March 20, at 7:00 PM. The program will be held at Winthrop’s Community Outreach Center, located at 101 Mineola Boulevard at the corner of Second Street in Mineola. The speakers, who are two leading experts in the field of Parkinson’s, will provide information about the most advanced treatment options and will explain the evaluation process for treating the disease.

Nora L. Chan, MD, Director of the Movement Disorders Program at Winthrop, will discuss how to optimize the medical management of the disease, and address the nonmovement related issues of Parkinson’s, such as problems with cognition, depression, fatigue, and sleep.

Brian Synder, MD, will explain surgical techniques, including deep brain stimulation (DBS), an innovative, sophisticated technology that targets regions deep within the brain to control motor symptoms. A question and answer period will be included in the program.

Attendees are asked to arrive at 6:45 PM for registration. Parking and the entrance are available in the rear of the building. Seating is limited and pre-registration is required. To reserve a space, please call (516) 663-8300.

For information on other programs at the Hospital, please call 1-866-WINTHROP, or visit http://www.winthrop.org/communityprograms.

Original post:
Discover New Treatments For Parkinson's Disease

Source:
http://www.longevitymedicine.tv/feed/

Past Pregnancies May Protect Against MS

Study: Multiple Sclerosis Risk May Drop by 50% After First Pregnancy

By Brenda Goodman, MA WebMD Health News

Reviewed by Louise Chang, MD

March 7, 2012 — Pregnancy appears to play a strong role in whether or not a woman may develop the autoimmune disease multiple sclerosis (MS), according to a new study.

The study involved more than 800 women between the ages of 18 and 60. Nearly 300 of them had experienced a first episode of MS symptoms. The other women were healthy and were included for comparison.

Women in the study with at least one child had about half the risk of early MS symptoms compared to women without children. And that risk appeared to drop with each additional child. Women with three children had a 75% lower risk of early MS symptoms compared to women without children. In women with five or more children, risk of early symptoms was slashed by 94%.

Those benefits remained even after researchers accounted for other factors associated with the likelihood of developing MS, like level of education, smoking, skin damage and sun exposure, and certain susceptibility genes.

Researchers say they’re pretty sure that it is something about pregnancy — rather than being a parent or raising children — that’s protective, because they saw no difference in men.

The study is published in the journal Neurology.

Although it is already known that a woman with MS may see a decrease in her symptoms while pregnant, other large studies have not seen an association between pregnancies and MS. But researchers think that may have something to do with when women were included in the studies.

Continue reading here:
Past Pregnancies May Protect Against MS

Source:
http://www.longevitymedicine.tv/feed/

Great Lakes NeuroTechnologies Awarded Patent for Technology to Assess Parkinson’s Disease

VALLEY VIEW, Ohio, March 9, 2012 /PRNewswire/ –Great Lakes NeuroTechnologies announced today that they have received allowance of claims from the U.S. Patent Office for an application covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders. The claims cover a system and method of wireless patient-worn motion sensors that assess tremor, bradykinesia, rigidity, and dyskinesias associated with diseases like Parkinson’s and essential tremor. This innovative medical technology has applications for both in-clinic and home-based patient care, optimizing programming for deep brain stimulation, and providing quantitative endpoints to determine efficacy of clinical trials. When used in telemedicine applications, physicians utilize a web interface to track symptom responses and fluctuations.

To address the growing market need for standardized and ambulatory assessment of movement disorders, Great Lakes NeuroTechnologies has been committed to the commercialization of the Kinesia and Kinesia HomeView medical technology platforms since 2003. “The allowance of our patent claims continues a successful commercialization path for our Parkinson’s assessment systems intended to help physicians maximize therapeutic benefits and ultimately improve patient quality of life,” says Joseph P. Giuffrida, PhD, President. “Great Lakes NeuroTechnologies is uniquely positioned in the movement disorders market as a world leader in medical device development and manufacture of technologies to standardize, automate, and remotely capture patient assessments. This heightened intellectual property position builds on and protects our previous commercialization efforts and continued market growth.” Dr. Giuffrida also thanked the National Institute of Neurological Disorders and Stroke and the National Institute on Aging for their continued support of these technologies.

The company is committed to building its intellectual property portfolio which will cover new applications arising from several on-going clinical studies. “We have a broad range of patent applications in the pipeline and expect this to be the first of many to cover our innovative product base of movement disorder technologies,” says Brian Kolkowski, PhD, Executive Vice President and General Counsel. “In addition, this patent represents a first step as wecontinue with international filings to protect our technology portfolio to support our growth into international markets.”

About Great Lakes NeuroTechnologies Great Lakes NeuroTechnologies is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations and positively impacting quality of life for people worldwide.

Media Contact Amelia Earhart, Marketing Manager – 216-446-2413 – aaearhart@GLNeuroTech.com

Continue reading here:
Great Lakes NeuroTechnologies Awarded Patent for Technology to Assess Parkinson's Disease

Source:
http://www.longevitymedicine.tv/feed/

Multiple Sclerosis Awareness Week activities in Sanger

Contributed

The City of Sanger is coordinating with the National Multiple Sclerosis Society to recognize March 12 18 as MS Awareness Week.

The local MS chapter and volunteers will decorate downtown Sanger with orange colored ribbons on March 11 and will take them down on March 19.

If you would like to get involved contact Ana Hernandez at 439-2154 or seintern@nmss.org.

Symptoms may be mild (numbness in the limbs) or severe (paralysis, loss of vision). The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Today, new treatments and advances in research are giving hope to people affected by the disease. For more information about MS visit http://www.nationalMSsociety.org/cal.

The following are comments from the readers. In no way do they represent the view of thesangerherald.com .

You must register with a valid email to post comments. Only your Member ID will be posted with the comments.

More here:
Multiple Sclerosis Awareness Week activities in Sanger

Source:
http://www.longevitymedicine.tv/feed/

Pregnancy May Protect Against MS, Study Says

WEDNESDAY, March 7 (HealthDay News) — New research suggests that pregnancy may decrease women’s risk of developing multiple sclerosis.

“Even one pregnancy was associated with nearly a halving of risk [of developing MS symptoms],” said study author Anne-Louise Ponsonby, head of the environmental and genetic epidemiology and research group at Murdoch Children’s Research Institute in Melbourne, Australia. The team also found that women who were pregnant two or more times had only one-quarter of the risk of developing MS symptoms as those who were never pregnant.

The study was published online March 7 in the journal Neurology.

Previous research has found that pregnancy in women who already have MS — an autoimmune disorder — is linked with lower rates of relapse.

Ponsonby’s team found an association between pregnancy and a lower risk of MS symptoms, not a direct cause-and-effect link. They say, however, that this association may help explain why the incidence of MS in women has inched up over the past few decades, as more women delay pregnancy or have fewer babies or none at all.

The researchers evaluated information on 282 Australian men and women, aged 18 to 59, who had MS symptoms — which can include fatigue, numbness, balance or walking problems — but had not been diagnosed with the disease. The researchers looked at both the number of live births and pregnancies lasting at least 20 weeks in the women. They also recorded the number of children born to men. They compared those statistics to 542 men and women without MS symptoms.

No link was found between the number of children men had and their risk of MS symptoms. There was an association with women, however: the risk of developing MS symptoms decreased as the number of pregnancies increased.

The researchers couldn’t say exactly why pregnancy may lower MS risk, but they speculated it could be the increase in estrogen during pregnancy or the effect pregnancy has on inflammatory genes involved in MS.

The study was funded by the National Multiple Sclerosis Society and other organizations.

Women are more likely than men to develop MS. Having a close relative with MS also increases your risk. About 400,000 people in the United States have MS, according to the National Multiple Sclerosis Society.

Here is the original post:
Pregnancy May Protect Against MS, Study Says

Source:
http://www.longevitymedicine.tv/feed/

Commonly used dementia drugs can help more patients with Alzheimer’s

Public release date: 7-Mar-2012 [ | E-mail | Share ]

Contact: Katherine Barnes katherine.barnes@kcl.ac.uk 44-207-848-3076 King’s College London

The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer’s disease, can also help in moderate to severe patients, according to a report funded by the UK Medical Research Council (MRC) and the Alzheimer’s Society. The study suggests that extending treatment to this group could help treat twice as many sufferers worldwide. Encouragingly, the drug has greater positive benefits for patients more severely affected than for those in the earlier stages of dementia.

It is estimated that 18 million people worldwide suffer from Alzheimer’s disease, which is the most common cause of dementia. According to the World Health Organization, of the 35 million people currently living with dementia globally, 58% live in low- and middle-income countries and by 2050 this figure is projected to reach 71% of the total.

The multi-centre UK study, led by Professor Robert Howard at King’s College London, is the first trial to demonstrate the value of continued drug intervention for those patients with moderate to severe Alzheimer’s disease who have deteriorated beyond the point where donepezil is currently recommended.

The study, to be published in the New England Journal of Medicine, looked at two drugs: donepezil and memantine. Donepezil is the most commonly prescribed of the dementia drugs and is recommended for patients at the earliest stages of Alzheimer’s disease. Doctors are currently advised to stop prescribing donepezil when the disease progresses to become moderate to severe and until now there has been no clear evidence that continuing treatment is of benefit to patients.

Over the course of the trial, patients who continued to take donepezil showed considerably less decline in cognition memory, orientation, language function and function (retained ability to carry out simple daily tasks and self-care) than those taking a placebo drug. The benefits seen with continued treatment were clinically important and were greater than those previously seen in patients with less severe Alzheimer’s disease. Whilst the effect was slightly smaller, starting memantine treatment also resulted in significantly better cognitive and functional abilities compared with those taking a placebo.

Professor Robert Howard, lead author from the Institute of Psychiatry at King’s says: “As patients progress to more severe forms of Alzheimer’s disease, clinicians are faced with a difficult decision as to whether to continue or not with dementia drugs and, until now, there has been little evidence to guide that decision. For the first time, we have robust and compelling evidence that treatment with these drugs can continue to help patients at the later, more severe stages of the disease. We observed that patients who continued taking donepezil were better able to remember, understand, communicate and perform daily tasks for at least a year longer than those who stopped taking the drugs. These improvements were noticeable to patients, their caregivers and doctors. Both donepezil and memantine will soon be off patent and available in very cheap generic preparations. These findings will greatly increase the numbers of patients in the developed and developing world that we are able to treat.”

Professor Nick Fox, MRC Senior Clinical Fellow at the Institute of Neurology, University College London, says: “The number of people with Alzheimer’s disease and other forms of dementia is reaching critical levels. It has never been more important to invest in research which will enable doctors to make informed decisions based on the best evidence possible when deciding what treatments to give patients. The MRC has an ongoing commitment to the development of effective, safe treatments that will improve the quality of life for people with Alzheimer’s disease and their care givers.”

Professor Clive Ballard, Director of Research at Alzheimer’s Society, says: “Thanks to the Alzheimer’s drug donepezil, tens of thousands of people in the early to moderate stages of the condition are able to recognise their family for longer, play with their grandchildren and make vital plans for the future. This major new trial now shows that there could also be significant benefits on continuing the treatment into the later stages too. There are 750,000 people with dementia in the UK yet currently prescription levels of Alzheimer’s drugs are still low. If this is to change we have to improve the shocking diagnosis rates and ensure everyone is given the opportunity to try treatments.”

See the article here:
Commonly used dementia drugs can help more patients with Alzheimer's

Source:
http://www.longevitymedicine.tv/feed/

Donepezil And Memantine, Key Dementia Drugs, Should Be Used More: Study

By Kate Kelland

LONDON, March 7 (Reuters) – Pfizer’s dementia drug Aricept, already commonly used to treat mild to moderate Alzheimer’s disease, can also help patients with severe disease and should be used more widely and for longer, according to research published on Wednesday.

British scientists who studied the possible longer-term benefits of giving Aricept suggested that extending treatment could help twice as many Alzheimer’s sufferers worldwide.

The study also looked at another commonly used dementia drug called memantine, which is sold in the United States under the brand Namenda by Forest Laboratories and Germany’s Merz, and in Britain under the brand Ebixa by Danish group Lundbeck .

It found that keeping patients with moderate to severe Alzheimer’s on Aricept, or donepezil as it is known generically, or starting them on memantine treatment, meant they had significantly better cognitive and function abilities than patients taking a placebo or dummy pill.

An estimated 18 million people worldwide suffer from Alzheimer’s disease, which is the most common form of dementia. It is fatal brain disease that affects memory, thinking, behaviour and the ability to handle daily activities and is placing an increasingly heavy burden on societies and economies across the world.

According to the World Health Organisation, some 35 million people worldwide have dementia, and Alzheimer’s Disease International predicts that as populations age, dementia cases will almost double every 20 years to around 66 million in 2030 and 115 million in 2050.

The study, published in the New England Journal of Medicine, involved 295 Alzheimer’s patients in Britain who were assigned to one of four separate groups – one continuing to take donepezil, one stopping donepezil and getting a placebo, one stopping donepezil and starting memantine, and a fourth taking both drugs together.

Robert Howard, a professor at King’s College London who led the trial, said it was the first to show the value of continued drug treatment for patients with moderate to severe Alzheimer’s.

See more here:
Donepezil And Memantine, Key Dementia Drugs, Should Be Used More: Study

Source:
http://www.longevitymedicine.tv/feed/

Pregnancy seems to protect against multiple sclerosis

Women who have been pregnant two or more times had a reduced risk of developing the disease, study finds. (Paul Sakuma / Associated Press)

March 7, 2012, 1:17 p.m.

Pregnancy is known to cause a remission in symptoms of multiple sclerosis in women who have MS prior to becoming pregnant. Now a study has found that multiple pregnancies may help prevent MS from ever developing.

The study, published online Wednesday in the journal Neurology, reviewed information on 282 men and women who received a diagnosis of central nervous demyelination. That’s a condition that reflects early symptoms of MS but falls short of an actual MS diagnosis. The researchers compared those people to 542 healthy men and women.

They found that women who have been pregnant two or more times had a reduced risk of developing the disease. Women who had five or more pregnancies had one-twentieth the risk of developing MS compared with women who were never pregnant. There was no effect on men regarding their number of offspring and onset of the disease.

Rates of MS have increased over the last several decades. This increase could reflect the fact that women are having fewer children, said the lead author of the study, Anne-Louise Ponsonby of Murdoch Children’s Research Institute in Melbourne, Australia. It’s not clear what it is about pregnancy that protects against MS or causes its temporary remission. It’s likely that hormones play a role, and studies are underway looking at estrogen as a treatment for the illness. It’s also possible that immune changes that take place during pregnancy alter symptoms of the disease as well as the risk of developing it.

twitter.com/LATShariRoan

See the article here:
Pregnancy seems to protect against multiple sclerosis

Source:
http://www.longevitymedicine.tv/feed/